Resiliency in Total Joint Arthroplasty

Osteoarthritis Clinical Trial

Official title:

Resiliency in Total Joint Arthroplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04357262
• Other study ID #: 129070
• Status: Completed
• Phase: N/A
• Start date: March 5, 2020
• Est. completion date: January 12, 2022

Study information

• Verified date: July 2022
• Source: University of Utah
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators primary objective is to determine how does participation in StreaMD affect patient reported outcomes after Total Hip Arthroplasty (THA) or Total Knee Arthroplasty (TKA)?

Description:

Osteoarthritis is a leading cause of disability in the US. By conservative estimates, about 54 million adults in the US have doctor-diagnosed arthritis. The number of people expected to have arthritis by the year 2040 is more than 78 million. Total joint arthroplasty is considered the treatment of choice for end-stage osteoarthritis. Currently, more than 1 million hip and knee replacements are performed each year in the US. By 2030, primary THR is projected to grow 171% and primary TKR is projected to grow by up to 189%, for a projected 635,000 and 1.28 million procedures, respectively. The incidence of pre-operative psychological distress in this group of patients is reported between 30% and 60% and preoperative psychological distress is associated with poorer pain and functional outcomes after surgery. Resilience, characterized by an ability to bounce back or recover from stress, is increasingly recognized as a psychometric property affecting many outcomes' domains including outcomes after TJA. Better resilience could improve patients overall satisfaction with the procedure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: January 12, 2022
• Est. primary completion date: January 12, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• All patients aged 18 and older who are receiving a total hip or knee replacement.

Exclusion Criteria:

• Patients enrolled in the MyMobility study

• Patients who do not have cell phones with text messaging capability

• Non-English speaking patients

Related Conditions & MeSH terms

• Osteoarthritis

Intervention

Other:
• StreaMD
Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.

Locations

Country	Name	City	State
United States	University of Utah Orthopaedic Center	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient Reported Outcome Score (PROMIS) following THA or TKA	Patient reported outcome will consist of the Patient-Reported Outcomes Measurement Information System (PROMIS)	Follow Up Visits up to 2-Years
Primary	Patient Reported Outcome Score (HOOS Jr.) following THA or TKA	Patient reported outcome will consist of the hip disability and osteoarthritis outcome score (HOOS Jr.)	Follow Up Visits up to 2-Years
Primary	Patient Reported Outcome Score (KOOS Jr.) following THA or TKA	Patient reported outcome will consist of the knee injury and osteoarthritis outcome score (KOOS Jr.)	Follow Up Visits up to 2-Years